Russian International Reserves Fall $15.7 Billion in Week to Dec. 19

Delivering Value for Shareholders through Share Buyback Programs, Royalty Revenues, and Capital Plans - Research Report on

  Delivering Value for Shareholders through Share Buyback Programs, Royalty
    Revenues, and Capital Plans - Research Report on Abbott, PAREXEL, PDL
                 BioPharma, Health Net, and Molina Healthcare

PR Newswire

NEW YORK, June 21, 2013

NEW YORK, June 21, 2013 /PRNewswire/ --

Editor Note: For more information about this release, please scroll to bottom.

Today, Wall Street Reports announced new research reports highlighting Abbott
Laboratories (NYSE: ABT), PAREXEL International Corporation (NASDAQ: PRXL),
PDL BioPharma Inc. (NASDAQ: PDLI), Health Net, Inc. (NYSE: HNT), and Molina
Healthcare, Inc. (NYSE: MOH). Today's readers may access these reports free of
charge - including full price targets, industry analysis and analyst ratings -
via the links below.

Abbott Laboratories Research Report

On June 14, 2013, Abbott Laboratories (Abbott) announced that its Board of
Directors has approved a new share repurchase program of up to $3 billion of
the corporation's common stock. The new share repurchase program replaces the
previous $5 billion program, which was announced in October 2008, and was
recently completed. The purchases may be made from time to time, subject to
market conditions and regulatory considerations. On the same day, Abbott's
Board of Directors also declared a quarterly common dividend of $0.14 per
share, payable on August 15, 2013, to shareholders of record at the close of
business on July 15, 2013. The Full Research Report on Abbott Laboratories -
including full detailed breakdown, analyst ratings and price targets - is
available to download free of charge at:


PAREXEL International Corporation Research Report

On June 13, 2013, PAREXEL International Corporation (PAREXEL) announced that
Ingo Bank has been appointed as the Company's Senior Vice President and will
become Chief Financial Officer on September 1, 2013, after fiscal year-end
audited financial statements have been filed. He will join PAREXEL on July 8,
2013 after serving as Chief Financial Officer and Executive Vice President of
Philips Healthcare, a Royal Philips company. Banks will succeed outgoing Chief
Financial Officer James F. Winschel Jr., who will remain at the Company as
Senior Vice President and Chief Financial Officer until September 1, 2013,
after which he will serve as Executive Vice President until his planned
retirement in 2014.The Full Research Report on PAREXEL International
Corporation - including full detailed breakdown, analyst ratings and price
targets - is available to download free of charge at:


PDL BioPharma Inc. Research Report

On June 11, 2013, PDL BioPharma Inc. (PDL BioPharma) announced its royalty
revenue guidance for Q2 2013 (period ending June 30, 2013). The Company
expects royalty revenue of approximately $143 million, as compared to royalty
revenue of $126 million in Q2 2012. The Company stated that the projected
growth is driven by increased Q1 2013 sales for all licensed products for
which PDL BioPharma receives royalties in Q2 2013. According to PDL BioPharma,
worldwide sales of Avastin increased approximately 8% YoY in Q1 2013, and
ex-U.S. manufactured and sold Avastin's Q1 2013 sales represented 46% of total
Avastin sales, as compared to 20% in Q1 2012. Worldwide sales of Herceptin
increased approximately 7% YoY in Q1 2013, and ex-U.S. manufactured and sold
Herceptin's Q1 2013 sales represented 34% of total Herceptin sales, as
compared to 41% in Q1 2012. Worldwide sales for Lucentis increased
approximately 8% YoY, with all sales coming from inventory produced in the US.
Lastly, worldwide sales for Tysabri, a Biogen Idec product, increased
approximately 12% YoY in Q1 2013. Tysabri royalties are determined at a flat
rate as a percentage of sales regardless of location of manufacture or sale.
Avastin, Herceptin, Lucentis, Xolair, Perjeta, and Kadcyla (the Genentech
Products) are subject to a tiered royalty rate for product that is made or
sold in the US and a flat royalty rate of 3% for product that is manufactured
outside of the US (ex-US manufactured and sold). The Full Research Report on
PDL BioPharma Inc. - including full detailed breakdown, analyst ratings and
price targets - is available to download free of charge at:


Health Net, Inc. Research Report

On June 18, 2013, Health Net Foundation, Inc.'s (Health Net) charitable
foundation announced that it will provide a $200,000 grant to the Southern
California Education Fund (SCEF). This grant is intended to help the
organization launch a pilot program in the San Fernando and San Gabriel
valleys, called Connecting Families to Health Coverage and Care. The program
involves trained volunteer leaders in schools, places of worship, and
community groups, who will help enroll individuals and their family members
into health care coverage.The Full Research Report on Health Net, Inc. -
including full detailed breakdown, analyst ratings and price targets - is
available to download free of charge at:


Molina Healthcare, Inc. Research Report

On June 17, 2013, Molina Healthcare, Inc. (Molina Healthcare) announced that
through its wholly-owned subsidiary, Molina Center LLC, the Company has
successfully completed a sale and lease back transaction with the dedicated
net lease group of Angelo, Gordon & Co (AG) for $158 million. Under the terms
of the transaction, Molina Healthcare sold to AG its principal executive
offices in Long Beach, California, as well as an office building in Columbus,
Ohio, that houses the principal health plan operations of Molina Healthcare of
Ohio, the Company's wholly-owned subsidiary. Commenting on the sale, J. Mario
Molina, M.D., Chief Executive Officer of Molina Healthcare, said, "Consistent
with our long-term capital plan, this transaction unlocks additional capital,
allowing Molina Healthcare to fund future growth initiatives while remaining
committed to our mission of serving low-income families and individuals." The
Full Research Report on Molina Healthcare, Inc. - including full detailed
breakdown, analyst ratings and price targets - is available to download free
of charge at: []



1.This is not company news. We are an independent source and our views do
    not reflect the companies mentioned.
2.Information in this release is fact checked and produced on a best efforts
    basis and reviewed by a CFA. However, we are only human and are prone to
    make mistakes. If you notice any errors or omissions, please notify us
3.This information is submitted as a net-positive to companies mentioned, to
    increase awareness for mentioned companies to our subscriber base and the
    investing public.
4.If you wish to have your company covered in more detail by our team, or
    wish to learn more about our services, please contact us at
5.For any urgent concerns or inquiries, please contact us at
6.Are you a public company? Would you like to see similar coverage on your
    company? Send us a full investors' package to for consideration.


Content is researched, written and reviewed on a best-effort basis. This
document, article or report is prepared and authored by Equity News Network.
An outsourced research services provider has, through Chartered Financial
Analysts, only reviewed the information provided by Equity News Network in
this article or report according to the Procedures outlined by Equity News
Network. Equity News Network is not entitled to veto or interfere in the
application of such procedures by the outsourced provider to the articles,
documents or reports, as the case may be.


Equity News Network makes no warranty, expressed or implied, as to the
accuracy or completeness or fitness for a purpose (investment or otherwise),
of the information provided in this document. This information is not to be
construed as personal financial advice. Readers are encouraged to consult
their personal financial advisor before making any decisions to buy, sell or
hold any securities mentioned herein.


Equity News Network is not responsible for any error which may be occasioned
at the time of printing of this document or any error, mistake or shortcoming.
No liability is accepted by Equity News Network whatsoever for any direct,
indirect or consequential loss arising from the use of this document. Equity
News Network expressly disclaims any fiduciary responsibility or liability for
any consequences, financial or otherwise arising from any reliance placed on
the information in this document. Equity News Network does not (1) guarantee
the accuracy, timeliness, completeness or correct sequencing of the
information, or (2) warrant any results from use of the information. The
included information is subject to change without notice.

SOURCE Wall Street Reports

Contact: Phone #: +1-310-496-8071 (North America)
Press spacebar to pause and continue. Press esc to stop.